Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OM-85 for moderate atopic dermatitis in infants and young children
2021-003179-33Phase 2Terminated
- Sponsor
- OM Pharma
- Start
- Sep 2021
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in atopic dermatitis (AD) comparing Broncho Vaxom with Matched placebo (2 arms). Primary endpoint: Weekly area under the curve of EASI score to week 16. Started Sep 2021; status: terminated.
02
Drugs
om-85
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2021-003179-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003179-33.